EMPA-Kidney Seals SGLT2 Inhibitors as 'Foundational' for CKD

Empagliflozin's efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.
Medscape Medical News

source https://www.medscape.com/viewarticle/984439?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?